Clinical trials
Completed Anxiety Disorders trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
83 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 5 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 12 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 83 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ruhr University of Bochum | 8 |
| Charite University, Berlin, Germany | 6 |
| Universitätsklinikum Hamburg-Eppendorf | 6 |
| Heidelberg University | 4 |
| Eli Lilly and Company | 3 |
| Jacobs University Bremen gGmbH | 3 |
| Martin-Luther-Universität Halle-Wittenberg | 3 |
| Philipps University Marburg | 3 |
| Technische Universität Dresden | 3 |
| University Medicine Greifswald | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anxiety Disorders | 83 |
| Depressive Disorder | 10 |
| Pain | 8 |
| Generalized Anxiety Disorder | 5 |
| Mental Disorders | 4 |
| COVID-19 | 3 |
| Heart Failure | 3 |
| Pulmonary Disease, Chronic Obstructive | 3 |
| Schizophrenia | 3 |
| Somatoform Disorders | 3 |
Trials
Showing 1 to 25 of 83. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.